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about me without me.” Integral to this, is
how the quality and productivity challenge
will be met; securing re-investment to meet
the demand and improve quality and
outcomes. The Government plans to allow
patients to rate hospitals and clinical
departments according to the quality of
care they receive. In addition there will be a
focus on personalised care that reflects
individuals’ health and care needs, supports
carers and encourages strong local
partnerships. Patients will be in charge of
making decisions about their care and will
be able to choose which consultant-led
team, GP and treatment they have.3
Empowering patients to become involved in
choosing their treatment through integrated
care can help them achieve greater control.5
The GP Consortia will look
after an £80 billion budget and
by 2012 will take over
responsibilities from Primary
Care Trusts (PCTs), including
leadership of the existing QIPP
initiative. This initiative will
continue with even greater
urgency, but with a stronger
focus on general practice
leadership.
A radical new approach
The DH proposed a radical new
approach to healthcare that
includes protecting the
population from health threats;
empowering local leadership
encouraging responsibility
across society to improve health
and a focus on key outcomes.6
Healthcare providers and
RICHARD SHORNEY and Dr KAREN OUSEY discuss
how the specialty of tissue viability can align with the ideals of
the quality agenda. They argue that investment in tissue
viability leads to improvements in quality, reduced hospital
admissions and significant savings.
In the new NHS the effectiveness of
care provision needs be demonstrated,
with healthcare practice being aligned to
priorities for quality and true
measurements of care recorded. The
Department of Health (DH) and both
the previous Labour and present
coalition Government, have identified
the need to maintain and develop quality
in healthcare. One key area where
efficiency savings can be made is within
tissue viability services. For example, the
DH1 set out its ambition to eliminate all
avoidable pressure ulcers in NHS-
provided care and the National Patient
Safety Agency2 selected the prevention
and treatment of pressure ulcers as one
of its “10 for 2010” plans to reduce
levels of harm in ten high risk patient
safety areas.
Efficiency savings and elements of
the quality agenda, most noticeably
Quality, Innovation, Productivity and
Prevention (QIPP) have become
synonymous with healthcare. Most
recently the DH published the
challenges and opportunities to health
care providers and commissioners to
meet the quality agenda, ensuring that
efficiency savings are made to allow
reinvestment.3,4
The DH operating framework clearly
identifies the requirement for the
involvement of patients and the public
when planning services, allowing them
to understand how and where their
money is being spent and offering
greater choice and control of services.
The key is shared decision making,
summed up by the phrase “no decision
Tissue viability:
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commissioners will be expected to meet
the quality agenda through cost savings
while not being detrimental to patient
care. A major area of expenditure for the
acute and primary care sectors is tissue
viability, with costs being assessed by the
DH in 19977 as being over £80 million,
not including hosiery products, with that
figure increasing to £95 m over a two year
period.8 Posnett and Franks9 calculated
that 200,000 people in the UK had a
chronic wound with an estimated cost of
treatment being between £2.3 bn and
£3.1 bn per year. Additionally, wound
dressings account for about £120 m of
prescribing costs in primary care in
England each year,10 with prescription
costs for wound dressings in primary care
in England being estimated at £116 m in
the year to September 2009. Interestingly,
the Patient Association11 presented results
of a survey that sampled 79 Trusts and
identified that there were three times
more infection control nurses than tissue
viability nurses employed by Acute Trusts.
This was despite the fact that the Patient
Association estimated the cost of treating
healthcare associated infections in
‘Tissue viability is
currently a nurse-led
specialty with a
relatively low profile
– both publicly and
within the healthcare
system. The problem
lies with the indistinct
perception of what it
entails.’
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midwifery community that could
demonstrate a response to the
QIPP challenge.
Each HIA sets out the scale
of the challenge and the potential
opportunity in terms of
improvements to quality and
patient experience and reduction
in cost to the NHS. Many
healthcare Trusts and
organisations are using the HIAs
as measures of quality to form part
of their CQUIN targets. The key
aim of the CQUIN payment
framework is to help produce a
system which actively encourages
Trusts and organisations to focus
on quality improvements and
innovation in commissioning
decisions.14 In particular, the
“Your Skin Matters” HIA has
highlighted how nurses have
embraced this challenge.15
The tissue viability team at
NHS Newham has been
highlighted in this particular HIA,
through their prevention strategies
and correct management of
pressure ulcers that identified how
to reduce the number of people
with pressure damage admitted from
nursing homes to hospital. Pressure ulcers
are defined as “localised injury to the skin
and/or underlying tissue usually over a
bony prominence, as a result of pressure,
or pressure in combination with shear”.16
The majority of pressure ulcers are
avoidable in NHS care, yet many Trusts
still experience higher than average
incidence figures, hence the continuing
initiatives and targets being introduced.
Pressure ulcer incidence has been found
to be between 4% and 10% of patients
admitted to acute hospitals in the UK.17
Pressure ulcers not only represent a
reduced quality of life for patients, but
also cost average district general hospitals
in the UK between £600,000 and £3 m
per year.15
Prevention strategies
Evaluation from the Newham
initiative has identified a reduction
in admissions from 24-45 in
2008, to 0-12 in 2009, for
patients with pressure ulcers, a
50% reduction for the period
April-August 2008/9. This has
resulted in a cost saving of
£59,100, based on admission
costs of £199 per night with an
average of a nine night stay.
Calculating the returns on
investment for this project showed
that for every £1 NHS Newham
invested in their tissue viability
service they generated £51.56 of
benefit over a year. This figure is
hospital to be approximately £1 bn
compared to at least £1.4 bn to treat
pressure ulcers. What was of more
concern was that infection control nurses
act in an advisory capacity, as opposed to
the tissue viability nurse who has a more
active clinical role.
The National Tissue Viability Society
defines the specialty as “A growing
specialty that primarily considers all
aspects of skin and soft tissue wounds
including acute surgical wounds, pressure
ulcers and all forms of leg ulceration.
However, it is not just wound
management, it also covers a wide range
of organisational, political and
socioeconomic issues as well as
professional relationships and education.”
A nurse-led specialty
Tissue viability is currently a nurse-led
specialty with a relatively low profile –
both publicly and within the healthcare
system. The problem lies with the
indistinct perception of what it entails,
and the variable cost to the NHS of
typical disorders such as pressure ulcer
prevention and treatment, leg ulceration,
aspects of skin care and protecting at risk
skin.12 While there is currently no
consensus on what constitutes tissue
viability, areas of care covered include
managing acute and chronic wounds;
pressure ulcer prevention and
management; infection control in wound
care; and protecting skin at risk from
trauma.13
Much of what has been published
recently addresses and focuses on quality
from a strategic perspective. Despite this
it is important to put these theoretical
models into practice and make them fit
for purpose. Of equal importance is how
these theoretical, national ambitions and
ideals from the DH are transferred into
everyday practice and, indeed, who is
accountable for delivering on the metrics
of quality care. Although evidence-based
practice, which can be defined as an
integration of the best available evidence
obtained from research, clinical guidelines
in conjunction with clinical expertise,
does allows clinicians to justify their
methods, this alone is no guarantee of
quality outcomes.14
The DH white paper3 goes some way
to address this practice theory gap, but
areas of best practice and actual case
studies need to demonstrate how quality
can and should be measured. The launch
of the High Impact Actions (HIAs) for
nursing and midwifery in 2009 is an
example of how awareness of tissue
viability services has been raised.15
The project initially sought examples of
best practice from the nursing and
‘The majority of pressure ulcers are avoidable in NHS care, yet
many Trusts still experience higher than average incidence figures.’
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5(4): 10-12.
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17(3): 97-100.
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practice. Wounds UK. 6(3): 38-46.
15 NHS Institute for innovation and
improvement (2009) High Impact Actions
for nursing and midwifery. Coventry: NHS.
16 European Pressure Ulcer Advisory
Panel/National Pressure Ulcer Advisory
Panel(2009) Prevention and treatment of
pressureulcers: quick reference guide.
European PressureUlcer Advisory Panel and
National PressureUlcer Advisory Panel,
Washington DC.
17 Clark M., Bours G. and Defloor T. (2004)
ThePrevalence of Pressure Ulcers in
Europe.In: Clark M., ed. Recent Advances in
TissueViability. Quay Books, MA Healthcare
Ltd, London.
It is the responsibility of healthcare
providers to provide evidence of
achievement of quality and innovation
within their practices to assure that those
that are commissioning services are
aware of the value of service offered.
True investment in tissue viability can
lead to improvements in quality, reduced
hospital admissions and significant
savings. It is important that
commissioners work with their providers
to commission high quality care for all,
as demonstrated by NHS Newham
in implementing the Your skin matters
HIA. 
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based on direct costs of setting up the
project, additional employment costs of a
Band 7 nurse, the cost of treating
pressure ulcers, and the number of
pressure ulcers prevented. The calculation
does not take into account the additional
quality benefits such as improvement in
quality of life for elderly patients in
nursing homes.
Conclusion
The DH has clearly identified that it aims
to ensure the quality agenda is at the heart
of the NHS care delivered. It is the
responsibility of clinical leaders to ensure
that these ideals and expectations are met.
The HIAs are just one example of a
quality initiative which allows clinicians to
be accountable for their practice and
show through tangible and fiscal rationale
that their service is of high quality. Using
examples of best practice tissue viability
can and should align to the ideals of the
quality agenda, positioning the service
offered as both valued and of good
quality.
Despite the high costs associated with
tissue viability, including wound
management and treatment, it is an ideal
specialty for public, patient involvement
and development of metrics that align to
the quality agenda. It is essential that
multi-disciplinary teams work in close
collaboration across both the acute and
secondary sector to develop measures of
care that reflect evidence-based care while
maintaining and developing quality within
a budget that demands efficiency savings.
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‘Efficiency savings and
elements of the quality
agenda, most noticeably
Quality, Innovation,
Productivity and Prevention
(QIPP) have become
synonymous with
healthcare.’
‘The launch of the High Impact Actions for nursing and midwifery
in 2009 is an example of how awareness of tissue viability
services has been raised. The project initially sought examples
of best practice from the nursing and midwifery community that
could demonstrate a response to the QIPP challenge.’
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33M, Ioban and Clean-Trace are trademarks of the 3M Company.© 3M Health Care 2011.
With a reputation for innovation and a diverse range of over 1000 healthcare products
and services, 3M can help you focus on today`s most important issues:
Reducing the risk of HCAIs
? Draping solutions with added antimicrobial protection for a sterile surgical environment
? Innovative products for reliable monitoring of the sterilisation process
? Hospital hygiene management solutions for peace of mind that surfaces are really clean
effective cost management
? Essential range of everyday surgical products offer value with the performance you expect
? Customised procedure trays that meet your needs, and eliminate waste1
. . . and equipping and educating healthcare professionals
? Wide variety of product training and educational workshops delivered in person and online
? 3M AFPP Academy helping practitioners to improve personal effectiveness in the workplace
? Knowledgeable representatives and clinical nurse advisors available for advice and support
3M has been at the forefront of providing infection
prevention solutions for many years.
Visit our website for more information:
www.3m.co.uk/ip
1 Thompson R,Kelly,L.1992. Managing Resources in the Operating
Department. British Journal of Theatre Nursing, September 1992
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